BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Downes M, Evans RM, Loomba R. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab 2020;32:878-888.e6. [PMID: 32610095 DOI: 10.1016/j.cmet.2020.06.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Acharya C, Bajaj JS. Transmitting Diet-Related Microbial Benefit through Fecal Microbiota Transplant in NASH: Can Microbiota Cut Through the Fat?Hepatol Commun. 2020;4:1559-1561. [PMID: 33163828 DOI: 10.1002/hep4.1596] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhong X, Cui P, Jiang J, Ning C, Liang B, Zhou J, Tian L, Zhang Y, Lei T, Zuo T, Ye L, Huang J, Chen H. Streptococcus, the Predominant Bacterium to Predict the Severity of Liver Injury in Alcoholic Liver Disease. Front Cell Infect Microbiol 2021;11:649060. [PMID: 33816353 DOI: 10.3389/fcimb.2021.649060] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
5 Hartmann P. Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Front Physiol 2022;13:893074. [DOI: 10.3389/fphys.2022.893074] [Reference Citation Analysis]
6 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
7 Sadiq FA. Is it time for microbiome-based therapies in viral infections? Virus Res 2021;291:198203. [PMID: 33132161 DOI: 10.1016/j.virusres.2020.198203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
10 Poland JC, Flynn CR. Bile Acids, Their Receptors, and the Gut Microbiota. Physiology (Bethesda) 2021;36:235-45. [PMID: 34159805 DOI: 10.1152/physiol.00028.2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Arif M, Zhang C, Li X, Güngör C, Çakmak B, Arslantürk M, Tebani A, Özcan B, Subaş O, Zhou W, Piening B, Turkez H, Fagerberg L, Price N, Hood L, Snyder M, Nielsen J, Uhlen M, Mardinoglu A. iNetModels 2.0: an interactive visualization and database of multi-omics data. Nucleic Acids Res 2021;49:W271-6. [PMID: 33849075 DOI: 10.1093/nar/gkab254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
12 Dickson I. Microbiome signatures for cirrhosis and diabetes. Nat Rev Gastroenterol Hepatol 2020;17:532. [PMID: 32704165 DOI: 10.1038/s41575-020-0351-3] [Reference Citation Analysis]
13 Simon TG, Chan AT, Huttenhower C. Microbiome Biomarkers: One Step Closer in NAFLD Cirrhosis. Hepatology 2021;73:2063-6. [PMID: 33283299 DOI: 10.1002/hep.31660] [Reference Citation Analysis]
14 Liang G. Altered gut bacterial and metabolic signatures and their interaction in inflammatory bowel disease. Synth Syst Biotechnol 2021;6:377-83. [PMID: 34820530 DOI: 10.1016/j.synbio.2021.10.003] [Reference Citation Analysis]
15 Oka A, Ishimura N, Ishihara S. A New Dawn for the Use of Artificial Intelligence in Gastroenterology, Hepatology and Pancreatology. Diagnostics (Basel) 2021;11:1719. [PMID: 34574060 DOI: 10.3390/diagnostics11091719] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lin F, Rensing C, Pang Z, Zou J, Lin S, Letuma P, Zhang Z, Lin W. Metabolomic analysis reveals differential metabolites and pathways involved in grain chalkiness improvement under rice ratooning. Field Crops Research 2022;283:108521. [DOI: 10.1016/j.fcr.2022.108521] [Reference Citation Analysis]
17 Gedgaudas R, Bajaj JS, Skieceviciene J, Varkalaite G, Jurkeviciute G, Gelman S, Valantiene I, Zykus R, Pranculis A, Bang C, Franke A, Schramm C, Kupcinskas J. Circulating microbiome in patients with portal hypertension. Gut Microbes 2022;14:2029674. [PMID: 35130114 DOI: 10.1080/19490976.2022.2029674] [Reference Citation Analysis]
18 Zhang S, Wu P, Tian Y, Liu B, Huang L, Liu Z, Lin N, Xu N, Ruan Y, Zhang Z, Wang M, Cui Z, Zhou H, Xie L, Chen H, Sun J. Gut Microbiota Serves a Predictable Outcome of Short-Term Low-Carbohydrate Diet (LCD) Intervention for Patients with Obesity. Microbiol Spectr 2021;9:e0022321. [PMID: 34523948 DOI: 10.1128/Spectrum.00223-21] [Reference Citation Analysis]
19 Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Reference Citation Analysis]
20 Testerman T, Li Z, Galuppo B, Graf J, Santoro N. Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth. Hepatol Commun 2022. [PMID: 35344283 DOI: 10.1002/hep4.1944] [Reference Citation Analysis]
21 Zeng T, Yu X, Chen Z. Applying artificial intelligence in the microbiome for gastrointestinal diseases: A review. J Gastroenterol Hepatol 2021;36:832-40. [PMID: 33880762 DOI: 10.1111/jgh.15503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dinani AM, Kowdley KV, Noureddin M. Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. Hepatology 2021. [PMID: 33928671 DOI: 10.1002/hep.31869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
24 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
25 Liu Y, Méric G, Havulinna AS, Teo SM, Åberg F, Ruuskanen M, Sanders J, Zhu Q, Tripathi A, Verspoor K, Cheng S, Jain M, Jousilahti P, Vázquez-Baeza Y, Loomba R, Lahti L, Niiranen T, Salomaa V, Knight R, Inouye M. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab 2022:S1550-4131(22)00090-0. [PMID: 35354069 DOI: 10.1016/j.cmet.2022.03.002] [Reference Citation Analysis]
26 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
27 Carter JK, Bhattacharya D, Borgerding JN, Fiel MI, Faith JJ, Friedman SL. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. PLoS One 2021;16:e0244763. [PMID: 33395434 DOI: 10.1371/journal.pone.0244763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Sang C, Yan H, Chan WK, Zhu X, Sun T, Chang X, Xia M, Sun X, Hu X, Gao X, Jia W, Bian H, Chen T, Xie G. Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:637652. [PMID: 33708783 DOI: 10.3389/fmed.2021.637652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wang X, Liu H, Li Y, Huang S, Zhang L, Cao C, Baker PN, Tong C, Zheng P, Qi H. Altered gut bacterial and metabolic signatures and their interaction in gestational diabetes mellitus. Gut Microbes 2020;12:1-13. [PMID: 33222612 DOI: 10.1080/19490976.2020.1840765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, Meng L, Xin Y, Jiang X. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 2021;117:154712. [PMID: 33497712 DOI: 10.1016/j.metabol.2021.154712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
34 Almeida JI, Tenreiro MF, Martinez-Santamaria L, Aspizua SG, Gisbert JP, Alves PM, Serra M, Baptista PM. Hallmarks of the human intestinal microbiome on liver maturation and function. J Hepatol 2021:S0168-8278(21)02152-8. [PMID: 34715263 DOI: 10.1016/j.jhep.2021.10.015] [Reference Citation Analysis]
35 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
36 Wu S, Jiang P, Zhao XM, Chen WH. Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis. Cell Metab 2021;33:455-6. [PMID: 33657385 DOI: 10.1016/j.cmet.2021.02.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Gao H, Jin Z, Tang K, Ji Y, Suarez J, Suarez JA, Cunha E Rocha K, Zhang D, Dillmann WH, Mahata SK, Ying W. Microbial DNA Enrichment Promotes Adrenomedullary Inflammation, Catecholamine Secretion, and Hypertension in Obese Mice. J Am Heart Assoc 2022;:e024561. [PMID: 35112881 DOI: 10.1161/JAHA.121.024561] [Reference Citation Analysis]
38 Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Reference Citation Analysis]
39 Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, Park SH, Lee MS, Kim DJ, Kim HS, Suk KT. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. Int J Mol Sci 2021;23:426. [PMID: 35008852 DOI: 10.3390/ijms23010426] [Reference Citation Analysis]
40 Huda MN, Kim M, Bennett BJ. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes. Front Endocrinol (Lausanne) 2021;12:632335. [PMID: 33897618 DOI: 10.3389/fendo.2021.632335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Zheng G, Liu C, Deng Z, Wei Z, Zhao Y, Qi H, Xie X, Wu D, Zhang Z, Yang H. Identifying the role of exogenous amino acids in catalyzing lignocellulosic biomass into humus during straw composting. Bioresour Technol 2021;340:125639. [PMID: 34315126 DOI: 10.1016/j.biortech.2021.125639] [Reference Citation Analysis]
42 Si J, Lee G, You HJ, Joo SK, Lee DH, Ku BJ, Park S, Kim W, Ko G. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. Comput Struct Biotechnol J 2021;19:5920-30. [PMID: 34849196 DOI: 10.1016/j.csbj.2021.10.032] [Reference Citation Analysis]
43 Evans RM, Lippman SM. Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell Metab. 2020;32:704-709. [PMID: 32941797 DOI: 10.1016/j.cmet.2020.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
44 Cheng X, Zhou L, Li Z, Shen S, Zhao Y, Liu C, Zhong X, Chang Y, Kermode AG, Qiu W. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence. Front Immunol 2022;13:827865. [DOI: 10.3389/fimmu.2022.827865] [Reference Citation Analysis]
45 Walker RL, Vlamakis H, Lee JWJ, Besse LA, Xanthakis V, Vasan RS, Shaw SY, Xavier RJ. Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med 2021;13:188. [PMID: 34915914 DOI: 10.1186/s13073-021-01007-5] [Reference Citation Analysis]
46 Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics 2021;53:336-48. [PMID: 34151600 DOI: 10.1152/physiolgenomics.00011.2021] [Reference Citation Analysis]
47 Oh TG, Kim SM, Atkins AR, Yu RT, Downes M, Evans RM, Loomba R. Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis. Cell Metab 2021;33:457. [PMID: 33657386 DOI: 10.1016/j.cmet.2021.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]